Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer

Molecular and Cellular Endocrinology

Volumn 418, Issue , 2015, Pages 264-272

  Anbalagan, Muralidharan ^a   Rowan, Brian G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Circadian disruption; Coregulators; Estrogen receptor; Phosphorylation; Src kinase

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SERINE; SERINE 118; SERINE 167; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA, HUMAN; PROTEIN BINDING;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CIRCADIAN RHYTHM; COMPLEX FORMATION; DISEASE ACTIVITY; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; LIGHT EXPOSURE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; BINDING SITE; BREAST TUMOR; CELL MOTION; CHEMISTRY; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PHOSPHORYLATION;

ANIMALS; BINDING SITES; BREAST NEOPLASMS; CELL MOVEMENT; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEIN BINDING;

EID: 84938308355     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.01.016     Document Type: Review

References (80)

1. Al-Dhaheri M.H., Rowan B.G. Application of phosphorylation site-specific antibodies to measure nuclear receptor signaling: characterization of novel phosphoantibodies for estrogen receptor alpha. Nucl. Recept. Signal 2006, 4:e007.
2. Al-Dhaheri M.H., Rowan B.G. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation. Mol. Endocrinol 2007, 21:439-456.
3. Anbalagan M., Carrier L., Glodowski S., Hangauer D., Shan B., Rowan B.G. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer. Breast Cancer Res. Treat 2012, 132:391-409.
4. Arnold S.F., Obourn J.D., Jaffe H., Notides A.C. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol. Endocrinol 1994, 8:1208-1214.
5. Arnold S.F., Obourn J.D., Jaffe H., Notides A.C. Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase II: consequence on DNA binding. J. Steroid Biochem. Mol. Biol 1995, 55:163-172.
6. Atsriku C., Britton D.J., Held J.M., Schilling B., Scott G.K., Gibson B.W., et al. Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Mol. Cell. Proteomics 2009, 8:467-480.
7. Bergqvist J., Elmberger G., Ohd J., Linderholm B., Bjohle J., Hellborg H., et al. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur. J. Cancer 2006, 42:1104-1112.
8. Bramlett K.S., Burris T.P. Effects of selective estrogen receptor modulators (SERMs) on coactivator nuclear receptor (NR) box binding to estrogen receptors. Mol. Genet. Metab 2002, 76:225-233.
9. Britton D.J., Scott G.K., Schilling B., Atsriku C., Held J.M., Gibson B.W., et al. A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells. J. Am. Soc. Mass Spectrom 2008, 19:729-740.
10. Bunone G., Briand P.A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15:2174-2183.
11. Castano E., Vorojeikina D.P., Notides A.C. Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation. Biochem. J. 1997, 326(Pt 1):149-157.
12. Chen D., Washbrook E., Sarwar N., Bates G.J., Pace P.E., Thirunuvakkarasu V., et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002, 21:4921-4931.
13. Chen H., Lin R.J., Schiltz R.L., Chakravarti D., Nash A., Nagy L., et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997, 90:569-580.
14. Chen M., Cui Y.K., Huang W.H., Man K., Zhang G.J. Phosphorylation of estrogen receptor alpha at serine 118 is correlated with breast cancer resistance to tamoxifen. Oncol. Lett 2013, 6:118-124.
15. Cheng J., Zhang C., Shapiro D.J. A functional serine 118 phosphorylation site in estrogen receptor-alpha is required for down-regulation of gene expression by 17beta-estradiol and 4-hydroxytamoxifen. Endocrinology 2007, 148:4634-4641.
16. Colditz G.A. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl Cancer Inst 1998, 90:814-823.
17. deGraffenried L.A., Chandrasekar B., Friedrichs W.E., Donzis E., Silva J., Hidalgo M., et al. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann. Oncol 2004, 15:885-890.
18. Dasgupta S., Lonard D.M., O'Malley B.W. Nuclear receptor coactivators: master regulators of human health and disease. Annu. Rev. Med 2014, 65:279-292.
19. Dauchy R.T., Xiang S., Mao L., Brimer S., Wren M.A., Yuan L., et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res 2014, 74:4099-4110.
20. Desouki M.M., Rowan B.G. SRC kinase and mitogen-activated protein kinases in the progression from normal to malignant endometrium. Clin. Cancer Res 2004, 15:546-555.
21. Duplessis T.T., Williams C.C., Hill S.M., Rowan B.G. Phosphorylation of estrogen receptor alpha at serine 118 directs recruitment of promoter complexes and gene-specific transcription. Endocrinology 2011, 152:2517-2526.
22. Dutertre M., Smith C.L. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Mol. Endocrinol 2003, 17:1296-1314.
23. Fagan D.H., Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13:423-429.
24. Feng W., Webb P., Nguyen P., Liu X., Li J., Karin M., et al. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. Mol. Endocrinol 2001, 15:32-45.
25. Filardo E.J., Quinn J.A., Frackelton A.R., Bland K.I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol 2002, 16:70-84.
26. Finn R.S. Targeting Src in breast cancer. Ann. Oncol 2008, 19:1379-1386.
27. Fu L., Lee C.C. The circadian clock: pacemaker and tumour suppressor. Nat. Rev. Cancer 2003, 3:350-361.
28. Hall J.M., McDonnell D.P., Korach K.S. Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol. Endocrinol 2002, 16:469-486.
29. Hankinson S.E., Colditz G.A., Willett W.C. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 2004, 6:213-218.
30. Hansen J., Stevens R.G. Case-control study of shift-work and breast cancer risk in Danish nurses: impact of shift systems. Eur. J. Cancer 2012, 48:1722-1729.
31. Hong H., Kohli K., Trivedi A., Johnson D.L., Stallcup M.R. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:4948-4952.
32. Hong H., Kohli K., Garabedian M.J., Stallcup M.R. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol. Cell. Biol 1997, 17:2735-2744.
33. Huderson B.P., Duplessis T.T., Williams C.C., Seger H.C., Marsden C.G., Pouey K.J., et al. Stable inhibition of specific estrogen receptor alpha (ERalpha) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells. Endocrinology 2012, 153:4144-4159.
34. Jiang J., Sarwar N., Peston D., Kulinskaya E., Shousha S., Coombes R.C., et al. Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin. Cancer Res 2007, 13:5769-5776.
35. Joel P.B., Traish A.M., Lannigan D.A. Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol. Endocrinol 1995, 9:1041-1052.
36. Joel P.B., Smith J., Sturgill T.W., Fisher T.L., Blenis J., Lannigan D.A. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol. Cell. Biol 1998, 18:1978-1984.
37. Kirkegaard T., Witton C.J., McGlynn L.M., Tovey S.M., Dunne B., Lyon A., et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol 2005, 207:139-146.
38. Kok M., Holm-Wigerup C., Hauptmann M., Michalides R., Stal O., Linn S., et al. Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer. J. Natl. Cancer Inst 2009, 101:1725-1729.
39. Landesman-Bollag E., Romieu-Mourez R., Song D.H., Sonenshein G.E., Cardiff R.D., Seldin D.C. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 2001, 20:3247-3257.
40. Lannigan D.A. Estrogen receptor phosphorylation. Steroids 2003, 68:1-9.
41. Le Romancer M., Poulard C., Cohen P., Sentis S., Renoir J.M., Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr. Rev 2011, 32:597-622.
42. Lefstin J.A., Yamamoto K.R. Allosteric effects of DNA on transcriptional regulators. Nature 1998, 392:885-888.
43. Leo C., Chen J.D. The SRC family of nuclear receptor coactivators. Gene 2000, 245:1-11.
44. Leo C., Li H., Chen J.D. Differential mechanisms of nuclear receptor regulation by receptor-associated coactivator 3. J. Biol. Chem 2000, 275:5976-5982.
45. Levin E.R. Membrane oestrogen receptor alpha signalling to cell functions. J. Physiol 2009, 587:5019-5023.
46. Li H., Gomes P.J., Chen J.D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:8479-8484.
47. Likhite V.S., Stossi F., Kim K., Katzenellenbogen B.S., Katzenellenbogen J.A. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol 2006, 20:3120-3132.
48. McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science 2002, 296:1642-1644.
49. Medunjanin S., Hermani A., De Servi B., Grisouard J., Rincke G., Mayer D. Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity. J. Biol. Chem 2005, 280:33006-33014.
50. Megdal S.P., Kroenke C.H., Laden F., Pukkala E., Schernhammer E.S. Night work and breast cancer risk: a systematic review and meta-analysis. Eur. J. Cancer 2005, 41:2023-2032.
51. Mukherjee R., Sun S., Santomenna L., Miao B., Walton H., Liao B., et al. Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor alpha. J. Steroid Biochem. Mol. Biol 2002, 81:217-225.
52. Munstermann U., Fritz G., Seitz G., Lu Y.P., Schneider H.R., Issinger O.G. Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. Eur. J. Biochem 1990, 189:251-257.
53. Murphy L., Cherlet T., Adeyinka A., Niu Y., Snell L., Watson P. Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. Clin. Cancer Res 2004, 10:1354-1359.
54. Murphy L.C., Niu Y., Snell L., Watson P. Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen. Clin. Cancer Res 2004, 10:5902-5906.
55. Murphy L.C., Seekallu S.V., Watson P.H. Clinical significance of estrogen receptor phosphorylation. Endocr. Relat. Cancer 2011, 18:R1-R14.
56. Nilsson S., Makela S., Treuter E., Tujague M., Thomsen J., Andersson G., et al. Mechanisms of estrogen action. Physiol. Rev 2001, 81:1535-1565.
57. Onate S.A., Tsai S.Y., Tsai M.J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270:1354-1357.
58. Park K.J., Krishnan V., O'Malley B.W., Yamamoto Y., Gaynor R.B. Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol. Cell 2005, 18:71-82.
59. Riggins R.B., Schrecengost R.S., Guerrero M.S., Bouton A.H. Pathways to tamoxifen resistance. Cancer Lett 2007, 256:1-24.
60. Rogatsky I., Trowbridge J.M., Garabedian M.J. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J. Biol. Chem 1999, 274:22296-22302.
61. Sabbah M., Courilleau D., Mester J., Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:11217-11222.
62. Savvidis C., Koutsilieris M. Circadian rhythm disruption in cancer biology. Mol. Med 2012, 18:1249-1260.
63. Schernhammer E.S., Laden F., Speizer F.E., Willett W.C., Hunter D.J., Kawachi I., et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J. Natl Cancer Inst 2001, 93:1563-1568.
64. Shah Y.M., Basrur V., Rowan B.G. Selective estrogen receptor modulator regulated proteins in endometrial cancer cells. Mol. Cell. Endocrinol 2004, 30:127-139.
65. Shah Y.M., Rowan B.G. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol. Endocrinol 2005, 19:732-748.
66. Skliris G.P., Nugent Z.J., Rowan B.G., Penner C.R., Watson P.H., Murphy L.C. A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer. Endocr. Relat. Cancer 2010, 17:589-597.
67. Song R.X., Zhang Z., Santen R.J. Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends Endocrinol. Metab 2005, 16:347-353.
68. Spencer T.E., Jenster G., Burcin M.M., Allis C.D., Zhou J., Mizzen C.A., et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997, 389:194-198.
69. Thomas R.S., Sarwar N., Phoenix F., Coombes R.C., Ali S. Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. J. Mol. Endocrinol 2008, 40:173-184.
70. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 1989, 59:477-487.
71. Torchia J., Rose D.W., Inostroza J., Kamei Y., Westin S., Glass C.K., et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 1997, 387:677-684.
72. Vendrell J.A., Bieche I., Desmetz C., Badia E., Tozlu S., Nguyen C., et al. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocr. Relat. Cancer 2005, 12:75-92.
73. Voegel J.J., Heine M.J., Zechel C., Chambon P., Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 1996, 15:3667-3675.
74. Ward R.D., Weigel N.L. Steroid receptor phosphorylation: assigning function to site-specific phosphorylation. Biofactors 2009, 35:528-536.
75. Weitsman G.E., Li L., Skliris G.P., Davie J.R., Ung K., Niu Y., et al. Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res 2006, 66:10162-10170.
76. Werner H., Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch. Physiol. Biochem 2009, 115:58-71.
77. Williams C.C., Basu A., El-Gharbawy A., Carrier L.M., Smith C.L., Rowan B.G. Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. BMC Biochem 2009, 10:36.
78. Yamashita H., Nishio M., Kobayashi S., Ando Y., Sugiura H., Zhang Z., et al. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res 2005, 7:R753-R764.
79. Yamashita H., Nishio M., Toyama T., Sugiura H., Kondo N., Kobayashi S., et al. Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr. Relat. Cancer 2008, 15:755-763.
80. Yamnik R.L., Holz M.K. mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett 2010, 584:124-128.